Search Results - "Patil, V. M."

Neoadjuvant chemotherapy followed by surgery in very locally advanced technically unresectable oral cavity cancers by Patil, V.M, Prabhash, K, Noronha, V, Joshi, A, Muddu, V, Dhumal, S, Arya, S, Juvekar, S, Chaturvedi, P, Chaukar, D, Pai, P, Kane, S, Patil, A, Agarwal, J.P, Ghosh-Lashkar, S, Dcruz, A

“…Summary Background The median survival of technically unresectable oral-cavity cancers (T4a and T4b) with non surgical therapy is 2–12 months. We hypothesized…”
Get full text

Current perspective of HCV NS5B inhibitors: a review by Patil, V M, Gupta, S P, Samanta, S, Masand, N

“…Hepatitis C virus (HCV) infection has emerged as one of the most significant disease to affect humans. Despite its large medical and economical impact, there…”
Get more information

Locoregional recurrences after post-operative volumetric modulated arc radiotherapy (VMAT) in oral cavity cancers in a resource constrained setting: experience and lessons learned by Chakraborty, S, Patil, V M, Babu, S, Muttath, G, Thiagarajan, S K

“…The conformal nature of dose distribution produced by volumetric modulated arc radiotherapy (VMAT) increases the risk of geographic miss. Data regarding…”
Get full text

Oral metronomic chemotherapy after definitive chemoradiation in esophageal squamous cell carcinoma: a randomized clinical trial by Noronha, V., Patil, V. M., Menon, N. S., Joshi, A., Goud, S., More, S., Kannan, S., Pawar, A., Nakti, D., Yadav, A., Shah, S., Mahajan, A., Janu, A., Kumar, R., Tibdewal, A., Mummudi, N., Agarwal, J. P., Banavali, S. D., Prabhash, K.

“…Background Improving outcomes in locally advanced esophageal/GEJ squamous cell cancer (SCC) is an unmet need. We investigated the addition of oral metronomic…”
Get full text

Can point doses predict volumetric dose to rectum and bladder: a CT-based planning study in high dose rate intracavitary brachytherapy of cervical carcinoma? by PATIL, V. M, PATEL, F. D, CHAKRABORTY, S, OINAM, A. S, SHARMA, S. C

“…Point doses, as defined by the International Commission on Radiation Units and Measurements (ICRU), are classically used to evaluate doses to the rectum and…”
Get full text

Retrospective analysis of palliative metronomic chemotherapy in head and neck cancer by Patil, V M, Noronha, V, Joshi, A, Nayak, L, Pande, N, Chandrashekharan, A, Dhumal, S, Bhattacharjee, A, Banavali, S, Prabhash, K

“…Metronomic chemotherapy has shown promising results in selected patients of head and neck cancer in a small randomized study. This retrospective analysis was…”
Get full text

Is there a role of induction chemotherapy followed by resection in T4b oral cavity cancers? by Joshi, A, Patil, V, Noronha, V, Juvekar, S, Deshmukh, A, Chatturvedi, P, Chaukar, D, Agarwal, J, Ghosh, S, Murthy, V, D′cruz, A, Prabhash, K

“…Objective: The objective of the following study is to investigate the efficacy and impact of induction chemotherapy in T4b oral cavity cancers. Materials and…”
Get full text

Novel 3,4-methylenedioxybenzene scaffold incorporated 1,3,5-trisubstituted-2-pyrazolines: Synthesis, characterization and evaluation for chemotherapeutic activity by Deshpande, S, Nagrale, S, Patil, M, Chavan, S

“…A series of novel 3, 4-methylenedioxybenzene scaffold incorporated 1,3,5-trisubstituted-2-pyrazoline derivatives was synthesised as potent antitubercular…”
Get full text

Utility of driver mutation by Sharma, V, Patil, V M, Noronha, V, Joshi, A, Prabhash, K

Get full text

Repeat biopsy in epidermal growth factor receptor mutation-positive nonsmall cell lung cancer: Feasibility, limitations, and clinical utility in Indian patients by Zanwar, S, Noronha, V, Joshi, A, Patil, V M, Chougule, A, Kumar, R, More, S, Goud, S, Janu, A, Mahajan, A, Prabhash, K

“…The feasibility and success rate of repeat biopsy for epidermal growth factor receptor (EGFR) mutation-positive lung cancers that have progressed on tyrosine…”
Get full text

Development and validation of a predictive score, for identifying poor eastern cooperative oncology group performance status (performance status 3–4) advanced nonsmall cell lung cancer patients who are likely to benefit from tyrosine kinase inhibitors by Joshi, A, Bhattacharjee, A, Noronha, V, Patil, V, Karpe, A, Kadam, N, Solanki, L, Prabhash, K

“…BACKGROUND: One of the ten advanced lung cancer patients presents with poor eastern cooperative oncology group performance status (ECOG PS). There are no clear…”
Get full text

Rechallenge temozolomide in glioma: A case series from India by Patil, V M, Tonse, R, Kothari, R, Chandrasekaran, A, Pande, N, Epari, S, Gupta, T, Jalali, R

“…Temozolomide (TMZ) is an integral part of upfront treatment of high-grade gliomas. It is administered postsurgery as concurrent therapy with radiation and…”
Get full text

Carboplatin-based concurrent chemoradiation therapy in locally advanced head and neck cancer patients who are unfit for cisplatin therapy by Noronha, V, Sharma, V, Joshi, A, Patil, V, Laskar, S, Prabhash, K

“…BACKGROUND: Cisplatin-based chemoradiation (CTRT) is the standard of care in locally advanced head and neck cancers. Limited treatment options are available in…”
Get full text

Comparison of paclitaxel-cetuximab chemotherapy versus metronomic chemotherapy consisting of methotrexate and celecoxib as palliative chemotherapy in head and neck cancers by Patil, V M, Noronha, V, Joshi, A, Agarwala, V, Muddu, V, Ramaswamy, A, Chandrasekharan, A, Dhumal, S, Juvekar, S, Arya, A, Bhattacharjee, A, Prabhash, K

“…The present match pair analysis was planned to compare the efficacy of cetuximab-paclitaxel-based chemotherapy versus metronomic therapy. Sixty patients with…”
Get full text

Induction chemotherapy in technically unresectable locally advanced oral cavity cancers: Does it make a difference? by Patil, V, Noronha, V, Muddu, V, Gulia, S, Bhosale, B, Arya, S, Juvekar, S, Chatturvedi, P, Chaukar, D, Pai, P, D′cruz, A, Prabhash, K

“…Background: Locally advanced and unresectable oral cavity cancers have a poor prognosis. Induction might be beneficial in this setting by reducing tumor bulk…”
Get full text

Expanded panel test detecting mesenchymal-epithelial transition amplification leading to effective treatment in adenocarcinoma lung by Noronha, V M, Jandyal, S, Joshi, A, Patil, V M, Mahajan, A, Prabhash, K

“…Sir, Expanded panel test beyond epidermal growth factor receptor (EGFR)/anaplastic lymphoma kinase (ALK)/c-ros oncogene 1 (ROS1) is recommended as part of…”
Get full text

Efficacy and safety of sorafenib in advanced renal cell cancer and validation of Heng criteria by Joshi, A, Ramaswamy, A, Noronha, V, Patil, V M, Chandrasekharan, A, Goel, A, Sahu, A, Sable, N, Agrawal, A, Menon, S, Prabhash, K

“…Sorafenib is an established upfront treatment option for metastatic RCC (mRCC). There is no published literature regarding its performance in Indian Patients…”
Get full text

Epidermal growth factor receptor positive lung cancer: The nontrial scenario by Noronha, V, Patil, V, Joshi, A, Tandon, N, Sharma, V, Ramaswamy, A, More, S, Gaud, S, Prabhash, K

“…PURPOSE: The aim of this study was to report the median overall survival (OS) in epidermal growth factor receptor (EGFR) mutation-positive patients who were…”
Get full text

Predictivity of human papillomavirus positivity in advanced oral cancer by Kane, S, Patil, V M, Noronha, V, Joshi, A, Dhumal, S, D'Cruz, A, Bhattacharjee, A, Prabhash, K

“…Human papillomavirus (HPV) is a known prognostic factor world over in patients of carcinoma oropharynx. The role of HPV in oral cancers has not been…”
Get full text

Head and neck cancer in geriatric patients: Analysis of the pattern of care given at a tertiary cancer care center by Thiagarajan, S, Babu, T P S, Chakraborthy, S, Patil, V M, Bhattacharjee, A, Balasubramanian, S

“…The percentage of elderly people with head and neck cancers (HNC) is on the rise. This makes HNC in this group of patients an important issue for healthcare…”
Get full text